Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances

Research output: Contribution to journalArticlepeer-review


Colleges, School and Institutes

External organisations

  • Centre for Liver Research, NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham B15 2TT, UK.


In 2016, obeticholic acid became the first new licensed therapy for primary biliary cholangitis in >20 years. This therapeutic came at a time of improved disease understanding from biliary and immunological mechanistic insights.


Original languageEnglish
Pages (from-to)76-78
Number of pages3
JournalNature Reviews. Gastroenterology & Hepatology
Issue number2
Early online date11 Jan 2017
Publication statusPublished - Feb 2017


  • obeticholic acid, Primary biliary cholangitis, cholangiocytes, Cholestatic liver disease, biliary